Loading...
XSHE002391
Market cap435mUSD
Jan 09, Last price  
5.02CNY
1D
0.60%
1Q
3.93%
Jan 2017
-56.92%
IPO
-65.44%
Name

Jiangsu Changqing Agrochemical Co Ltd

Chart & Performance

D1W1MN
XSHE:002391 chart
P/E
43.63
P/S
0.88
EPS
0.12
Div Yield, %
6.50%
Shrs. gr., 5y
3.79%
Rev. gr., 5y
3.79%
Revenues
3.61b
-14.83%
303,573,575414,784,321630,905,946676,314,453755,434,9251,001,151,8051,270,852,5471,568,668,8581,808,980,7611,820,809,2891,832,821,3592,245,305,8843,000,795,0693,377,169,6243,008,259,2563,764,717,6824,243,592,7633,614,477,683
Net income
73m
-72.13%
20,253,45245,817,98095,172,022101,127,897106,645,741113,444,563159,515,759192,546,092234,166,645237,561,333162,645,909227,898,176319,432,523370,835,681194,959,420248,534,907262,351,11673,113,919
CFO
-78m
L
24,315,94436,538,437163,744,46725,120,95804,945,195164,152,783205,124,973225,446,946182,576,373194,177,456515,069,727608,574,446374,438,900347,133,347428,704,958845,087,235-77,891,755
Dividend
Jun 21, 20240.2 CNY/sh
Earnings
May 08, 2025

Profile

Jiangsu Changqing Agrochemical Co., Ltd. manufactures and sells pesticides in China, Europe, the United States, and Southeast Asia. Its technical materials comprise fomesafen, acifluorfen, fluoroglycofen-ethyl, lactofen, clomazone, imazethapyr, bromoxynil octanoate, nicosulfuron, benazolin-ethyl, clethodim, tricyclazole, fenoxanil, imidacloprid, acetamiprid, diafenthiuron, mesotrione, s-metolachlor, clodinafop-propargyl, dicamba, indoxacarb, fipronil, thiamethoxam, indoxacarb technical concentrate, clethodim mother liquor, cyhalofop-butyl active compound, prosulfuron active compound, pretilachlor active compound, azoxystrobin active compound, glyphosate active compound, chlorpyrifos active compound, triazophos, dimethazone, and triasulfuron active compound materials; and formulations include insecticides, bactericides, and herbicides. The company is based in Yangzhou, China.
IPO date
Apr 16, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,614,478
-14.83%
4,243,593
12.72%
Cost of revenue
3,318,524
3,803,315
Unusual Expense (Income)
NOPBT
295,954
440,277
NOPBT Margin
8.19%
10.38%
Operating Taxes
(16,279)
9,558
Tax Rate
2.17%
NOPAT
312,233
430,719
Net income
73,114
-72.13%
262,351
5.56%
Dividends
(207,273)
(129,921)
Dividend yield
5.06%
2.85%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,337,751
867,485
Long-term debt
678,560
822,672
Deferred revenue
7,119
8,230
Other long-term liabilities
158,737
Net debt
1,261,821
639,869
Cash flow
Cash from operating activities
(77,892)
845,087
CAPEX
(1,036,205)
Cash from investing activities
(535,995)
Cash from financing activities
589,856
FCF
(467,879)
105,441
Balance
Cash
675,732
1,050,288
Long term investments
78,758
Excess cash
573,765
838,109
Stockholders' equity
2,189,520
2,507,553
Invested Capital
6,189,329
5,491,278
ROIC
5.35%
8.09%
ROCE
4.38%
6.95%
EV
Common stock shares outstanding
649,593
649,593
Price
6.30
-10.38%
7.03
-13.00%
Market cap
4,092,433
-10.38%
4,566,636
-11.25%
EV
5,356,613
5,219,138
EBITDA
651,773
749,269
EV/EBITDA
8.22
6.97
Interest
68,848
59,053
Interest/NOPBT
23.26%
13.41%